TAVR: Minimalist Approach Proven Safe and Effective 09/01/25

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like PRADA II trial and breast cancer. Key takeaway: TAVR: Minimalist Approach Proven Safe and Effective. Article Links: Article 1: Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. (Circulation) Article 2: Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants. (Circulation) Article 3: Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial. (Circulation) Article 4: Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling. (Circulation) Article 5: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. (European heart journal) Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/tavr-minimalist-approach-proven-safe-and-effective-09-01-25/ Full Episode Summary This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details. Featured Articles Article 1: Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884047 Summary: This trial investigated the use of sacubitril-valsartan, an angiotensin receptor neprilysin inhibitor, to prevent cardiac dysfunction in breast cancer patients undergoing anthracycline and trastuzumab therapy. The study found that sacubitril-valsartan did not significantly reduce the incidence of cancer therapy-related cardiac dysfunction compared to placebo, indicating no significant cardioprotective benefit in this setting. The findings suggest alternative strategies are needed to mitigate cardiotoxicity in breast cancer patients receiving these treatments. Article 2: Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40879562 Summary: This research explored the role of intermediate effect variants, or IEVs, in the genetic architecture of Hypertrophic Cardiomyopathy. The study suggests that IEVs, while not individually causative, can significantly modulate disease expression and contribute to the overall phenotype. Understanding the impact of these IEVs is crucial for a more comprehensive understanding of the complex genetic basis of Hypertrophic Cardiomyopathy. Article 3: Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40878766 Summary: The DOUBLE-CHOICE trial compared a minimalist approach to transcatheter aortic valve implantation with standard of care in patients with symptomatic aortic stenosis. The study demonstrated non-inferiority of the minimalist approach, indicating that it is a safe and effective alternative to standard of care. This suggests a potential shift towards less invasive strategies for transcatheter aortic valve implantation. Article 4: Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40878676 Summary: This study investigated the mechanisms behind antiphospholipid syndrome vasculopathy, characterized by abnormal proliferation of endothelial and smooth muscle cells in small blood vessels. The research identified that microvascular endothelial cells drive the vasculopathy through YAP1 and CCN2 mediated signaling pathways. These findings offer potential targets for developing new treatments for patients with antiphospholipid syndrome vasculopathy. Article 5: Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. Journal: European heart journal PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886179 Summary: The TAILORED-CHIP trial investigated tailored antiplatelet strategies involving temporal modulation of platelet inhibition intensity in high-risk patients undergoing complex percutaneous coronary intervention. The trial found that the tailored antiplatelet strategy did not reduce major adverse cardiovascular events compared to standard dual antiplatelet therapy. The study suggests that a tailored approach based on platelet function testing may not provide superior outcomes in this patient population. Transcript Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings. Article number one. Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial. This trial investigated the use of sacubitril-valsartan, an angiotensin receptor neprilysin inhibitor, to prevent cardiac dysfunction in breast cancer patients undergoing anthracycline and trastuzumab therapy. The study found that sacubitril-valsartan did not significantly reduce the incidence of cancer therapy-related cardiac dysfunction compared to placebo, indicating no significant cardioprotective benefit in this setting. The findings suggest alternative strategies are needed to mitigate cardiotoxicity in breast cancer patients receiving these treatments.Article number two. Redefining the Genetic Architecture of Hypertrophic Cardiomyopathy: Role of Intermediate Effect Variants. This research explored the role of intermediate effect variants, or IEVs, in the genetic architecture of Hypertrophic Cardiomyopathy. The study suggests that IEVs, while not individually causative, can significantly modulate disease expression and contribute to the overall phenotype. Understanding the impact of these IEVs is crucial for a more comprehensive understanding of the complex genetic basis of Hypertrophic Cardiomyopathy.Article number three. Peri-interventional Anesthesia Strategies for Transcatheter Aortic Valve Implantation: A Multicenter, Randomized, Controlled, Non-inferiority Trial. The DOUBLE-CHOICE trial compared a minimalist approach to transcatheter aortic valve implantation with standard of care in patients with symptomatic aortic stenosis. The study demonstrated non-inferiority of the minimalist approach, indicating that it is a safe and effective alternative to standard of care. This suggests a potential shift towards less invasive strategies for transcatheter aortic valve implantation.Article number four. Microvascular Endothelial Cells License APS Vasculopathy Through YAP1- and CCN2-Mediated Signaling. This study investigated the mechanisms behind antiphospholipid syndrome vasculopathy, characterized by abnormal proliferation of endothelial and smooth muscle cells in small blood vessels. The research identified that microvascular endothelial cells drive the vasculopathy through YAP1 and CCN2 mediated signaling pathways. These findings offer potential targets for developing new treatments for patients with antiphospholipid syndrome vasculopathy.Article number five. Temporal modulation of antiplatelet therapy in high-risk patients undergoing complex percutaneous coronary intervention: the TAILORED-CHIP randomized clinical trial. The TAILORED-CHIP trial investigated tailored antiplatelet strategies involving temporal modulation of platelet inhibition intensity in high-risk patients undergoing complex percutaneous coronary intervention. The trial found that the tailored antiplatelet strategy did not reduce major adverse cardiovascular events compared to standard dual antiplatelet therapy. The study suggests that a tailored approach based on platelet function testing may not provide superior outcomes in this patient population. Thank you for listening. Tap ‘more’ for full notes and links. Keywords PRADA II trial, breast cancer, microvascular endothelial cells, TAILORED-CHIP trial, antiplatelet therapy, Hypertrophic Cardiomyopathy, CCN2 signaling, genetic architecture, percutaneous coronary intervention, vasculopathy, sarcomere genes, cardiotoxicity, angiotensin receptor neprilysin inhibitor, antiphospholipid syndrome, intermediate effect variants, DOUBLE-CHOICE trial, disease expression, platelet inhibition, sacubitril-valsartan, transfemoral transcatheter aortic valve implantation, transcatheter aortic valve implantation, aortic stenosis, dual antiplatelet therapy, YAP1 signaling, minimalist approach. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post TAVR: Minimalist Approach Proven Safe and Effective 09/01/25 first appeared on Cardiology Today.